Genentech Inc (Genentech) is a biotech company that undertakes discovery, development, manufacture and commercialization of medicines for the treatment of patients with serious medical conditions. The company focuses on developing drugs for unmet medical needs in the areas of oncology, immunology, neuroscience, metabolism, infectious disease, ophthalmology and bioinformatics. Some of its products include Rituxan, Avastin, Herceptin, Tarceva, Lucentis, Xolair, Pulmozyme, Activase and others. Genentech research activities focus on areas of cancer, metabolism, immunology, infectious disease and neuroscience. Its clinical development pipeline includes small molecules, monoclonal antibodies, and antibody drug conjugates. The company operates as a wholly owned subsidiary of Roche. Genentech is headquartered in South San Francisco, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company Genentech Inc - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Our reports have been used by over 10K customers, including:
C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019 Summary C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)...
Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019 Summary According to the recently published report ’Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019’; Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes...
The Global Cancer Monoclonal Antibody Partnering 2014-2019: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer monoclonal antibody partnering...
219 pages •
By Asia Market Information & Development Company
• Oct 2019
China’s demand for Monoclonal Antibody has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019 Summary Medical Devices sector report, “Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019" provides an overview of Retrovirus Rapid Tests & Point of Care (POC) currently...
Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019 Summary Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 25 molecules. Out of which approximately...
Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2019 Summary Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357...
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.